Literature DB >> 9230739

Respiratory response to CO2 during pressure-support ventilation in conscious normal humans.

D Georgopoulos1, I Mitrouska, Z Bshouty, K Webster, D Patakas, M Younes.   

Abstract

The respiratory response to CO2 during pressure-support ventilation (PSV) was studied in 16 conscious normal humans. The subjects breathed through a mouthpiece connected to a ventilator in PSV mode, with pressure set to the highest comfortable level for each subject (10.1 +/- 0.6 cm H2O, mean +/- SE). Compared with breathing spontaneously through the ventilator (CPAP mode with zero positive end-expiratory pressure), with PSV, tidal volume (VT) increased significantly (1.16 +/- 0.1 versus 0.85 +/- 0.04 L), whereas breathing frequency (f) remained stable (16.0 +/- 0.9 versus 15.6 +/- 1.1 breaths/min). As a result, the subjects hyperventilated, decreasing significantly end-tidal PCO2 (PETCO2, 23.5 +/- 1.2 versus 35.5 +/- 1.1 mm Hg). Fraction of inspired CO2 (FICO2) was then increased in steps, and changes in respiratory motor output were quantitated from changes in f, VT, ventilation (VI), peak inspiratory flow (Vpeak), and muscle pressure (Pmus). Pmus was calculated by the equation of motion, based on respiratory system mechanics, which were measured previously by airway occlusion at end-inspiration, VT, VI, and Pmus increased significantly with increasing PETCO2, and the response was detectable even below eupneic levels; f remained relatively stable over a wide range of PETCO2 (23 to 45 mm Hg) and increase significantly only when PETCO2 approached 50 mm Hg. These results indicate that in conscious normal humans during PSV, CO2 responsiveness extends well into hypocapnia and is expressed principally as an increase in intensity of respiratory motor output with little change in respiratory rate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230739     DOI: 10.1164/ajrccm.156.1.9606055

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Bilevel positive airway pressure ventilation: factors influencing carbon dioxide rebreathing.

Authors:  Zbigniew Szkulmowski; Kheirallah Belkhouja; Quoc-Hung Le; Dominique Robert; Laurent Argaud
Journal:  Intensive Care Med       Date:  2010-02-11       Impact factor: 17.440

2.  Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice.

Authors:  Marie A Toward; Ana P Abdala; Sharon J Knopp; Julian F R Paton; John M Bissonnette
Journal:  Exp Physiol       Date:  2012-11-23       Impact factor: 2.969

3.  Evaluation of carbon dioxide rebreathing during exercise assisted by noninvasive ventilation with plateau exhalation valve.

Authors:  Yong-Er Ou; Zhi-Min Lin; Dong-Ming Hua; Ying Jiang; Ya-Ting Huo; Qun Luo; Rong-Chang Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-01-16

Review 4.  Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions.

Authors:  Elena Spinelli; Tommaso Mauri; Jeremy R Beitler; Antonio Pesenti; Daniel Brodie
Journal:  Intensive Care Med       Date:  2020-02-03       Impact factor: 17.440

5.  Titration and characteristics of pressure-support ventilation use in Argentina: an online cross-sectional survey study.

Authors:  Joaquin Pérez; Javier Hernán Dorado; Ana Carolina Papazian; Maricel Berastegui; Daniela Inés Gilgado; Gimena Paola Cardoso; Cristian Cesio; Matías Accoce
Journal:  Rev Bras Ter Intensiva       Date:  2020-05-08

Review 6.  Neurally Adjusted Ventilatory Assist in Acute Respiratory Failure-A Narrative Review.

Authors:  Michele Umbrello; Edoardo Antonucci; Stefano Muttini
Journal:  J Clin Med       Date:  2022-03-28       Impact factor: 4.241

Review 7.  Proportional modes of ventilation: technology to assist physiology.

Authors:  Annemijn H Jonkman; Michela Rauseo; Guillaume Carteaux; Irene Telias; Michael C Sklar; Leo Heunks; Laurent J Brochard
Journal:  Intensive Care Med       Date:  2020-08-11       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.